PT-141, also called bremelanotide, is a melanocortin receptor agonist used for sexual desire concerns. The FDA-approved product, Vyleesi, is for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. Online “research use only” peptides are not for human use. Safer access requires clinician review and a prescription when appropriate 1.
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →Can you buy PT-141 online legally and safely?
PT-141 can be accessed online more safely when the path includes a licensed clinician, a prescription when appropriate, and dispensing through a state-licensed pharmacy. The risky route is buying “research-use-only” peptide vials from websites that say the product is not for human use, even if the page looks polished.
Bremelanotide has an FDA-approved product, Vyleesi, for a specific group: premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD, that is not due to another medical, psychiatric, relationship, or medication cause 1. That label does not make every PT-141 product online approved, studied, or appropriate for every person.
Why prescription access is different from research-use peptide websites
Prescription access starts with a health history and a clinician deciding whether bremelanotide makes sense for the person. Research-use peptide sites often label PT-141 as a laboratory chemical for receptor or assay work, and some explicitly say “not for human use” 7, 8.
That difference matters because PT-141 can affect blood pressure and heart rate. The Vyleesi label reports transient increases in blood pressure and reductions in heart rate after dosing and says it is contraindicated in people with uncontrolled hypertension or known cardiovascular disease 1.
What to check before trusting any online PT-141 source
- Is a licensed clinician reviewing your health history before any prescription is issued?
- Is the product dispensed by a state-licensed pharmacy, not sold as a research chemical?
- Does the site explain who may not be a candidate, including people with uncontrolled blood pressure or cardiovascular disease?
- Does the site avoid promising desire, performance, or relationship outcomes?
- Does it clearly state whether the product is FDA-approved, compounded, or research-use-only?
What is PT-141 used for?
PT-141 is used and studied mainly in sexual-desire disorders, especially HSDD in women. The strongest formal evidence and FDA approval are for bremelanotide injection in certain premenopausal women, not as a general libido enhancer for everyone 1.
PT-141 for hypoactive sexual desire disorder
HSDD means persistent low or absent sexual desire that causes meaningful personal distress or relationship difficulty. Reviews describe HSDD as multifactorial, with biological, psychological, relationship, medication, and hormone-related contributors 2.
In the RECONNECT phase 3 trials, premenopausal women with HSDD were randomized to bremelanotide 1.75 mg subcutaneous injection or placebo as needed before sexual activity; bremelanotide improved sexual desire and reduced distress scores more than placebo, though individual results varied 3. Side effects were common, especially nausea, flushing, and headache, so benefits and tolerability have to be weighed together 1, 3.
What HSDD means and why distress matters
Low libido alone is not always a disorder. Clinical definitions of HSDD include distress, duration, context, and whether the concern is better explained by another issue, such as depression, pain, relationship stress, hormone changes, or a medication side effect 2, 4.
What is known and not known about PT-141 for men or erectile dysfunction
Bremelanotide has been studied in men with erectile dysfunction, including early trials that tested it alone and with sildenafil, but it is not FDA-approved for erectile dysfunction 5, 6. For men, the honest answer is that evidence exists, but it is less definitive than the HSDD data used for the approved Vyleesi indication.
Why PT-141 is not the same as Viagra or Cialis
Sildenafil and tadalafil are PDE5 inhibitors that mainly affect blood-flow signaling in erectile tissue. Bremelanotide is a melanocortin receptor agonist that acts through central nervous system pathways tied to desire and arousal, so it is not simply another version of Viagra or Cialis 1, 6.
How does PT-141 work in the body?
Bremelanotide activates melanocortin receptors, including pathways involving MC3R and MC4R, in the central nervous system. In plain language, it works more on brain signaling tied to sexual desire and arousal than on local blood-flow mechanics 2.
Melanocortin receptors and central nervous system signaling
Melanocortin receptors are cell receptors involved in several body systems, including appetite, pigmentation, inflammation, and sexual response. Bremelanotide is described as a melanocortin receptor agonist, which means it turns on certain melanocortin receptor signals rather than blocking them 2.
Desire and arousal versus blood-flow mechanics
This central mechanism is why PT-141 is often discussed for low desire, not only erection firmness. But mechanism is not destiny: sexual function is shaped by sleep, stress, pain, relationship safety, hormones, medications, and mental health, so a receptor pathway does not guarantee a result for every person 4.
PT-141, Vyleesi, compounded PT-141, and research peptides: what is the difference?
PT-141 is the peptide name many people search online; bremelanotide is the drug name; Vyleesi is the FDA-approved brand product for a defined indication. Compounded PT-141 and research-use PT-141 are different categories with different oversight and different risks.
| Category | What it is | FDA status | Typical access path | Key safety point |
|---|---|---|---|---|
| Vyleesi | Brand bremelanotide subcutaneous injection | FDA-approved for acquired, generalized HSDD in certain premenopausal women | Prescription after clinician evaluation | Label warns about nausea and temporary blood pressure and heart-rate changes |
| Compounded PT-141 | A patient-specific compounded bremelanotide formulation, such as nasal spray when listed by a clinic | Not FDA-approved; not reviewed by FDA for safety, effectiveness, or quality before dispensing | Prescription, when appropriate, through a licensed clinician and state-licensed 503A pharmacy | Quality depends on lawful prescribing, pharmacy standards, and follow-up |
| Research-use-only PT-141 peptides | Laboratory research material sold online, often as vials | Not approved for human use | Online checkout without real clinical care | Labels may state not for human or animal use; should not be used for self-treatment |
Why research-use-only labels matter
A research-use-only label is not a small detail. Examples of PT-141 peptide listings describe the product as laboratory-grade, intended for controlled research programs, or not for human use 7, 8.
What compounded medication quality oversight can and cannot mean
Compounded medications can be appropriate when prescribed for an individual patient and prepared by a licensed compounding pharmacy, but they are not FDA-approved products. The FDA explains that compounded drugs do not undergo FDA premarket review for safety, effectiveness, or quality 9.
3-min quiz
Considering PT-141 with clinician review?
Chia offers PT-141 nasal spray through a 100% online visit. A licensed US provider reviews your health history and prescribes only when clinically appropriate; a prescription is not guaranteed. Compounded drugs are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality before dispensing.
How do you get PT-141 through Chia?
Chia currently offers compounded PT-141 as nasal spray, not injection, with plans currently starting from $159/mo. The process is online, but it is still medical care: a licensed provider reviews your information and prescribes only when appropriate.
PT-141 nasal spray at Chia
At Chia, PT-141 is listed as PT-141 nasal spray. It is also the treatment in our Spark protocol, which currently starts from $159/mo. We do not list PT-141 injections in the current catalog.
| Chia option | Listed form | Current starting price | How prescribing works |
|---|---|---|---|
| PT-141 product | Nasal spray | From $159/mo | Online questionnaire, licensed provider review, prescription only if clinically appropriate |
| Spark protocol | PT-141 nasal spray | From $159/mo | Same clinician-reviewed online process with home delivery when prescribed |
Online health questionnaire and licensed provider review
You start with a short health questionnaire through the Chia eligibility quiz. Our providers review medical history, current medications, blood pressure or cardiovascular risk when relevant, and whether low libido may have another cause.
When a prescription may or may not be appropriate
A prescription may not be appropriate if symptoms point to another condition, if risks outweigh likely benefit, or if the person has a contraindication such as uncontrolled hypertension or known cardiovascular disease, which are contraindications in the Vyleesi label 1. If prescribed, dosing and follow-up are provider-guided through the patient portal.
How shipping through state-licensed 503A compounding pharmacies works
When clinically appropriate, Chia prescriptions are compounded in the US by state-licensed 503A compounding pharmacies and shipped to the patient’s door. That is different from buying research peptides without a prescription or clinical follow-up.
When to use the Chia quiz or DoctorMCP for prescription access
Most patients can start with the eligibility quiz. If an AI agent is helping you organize prescription access, Chia can also be reached through DoctorMCP at mcp.chia.health as a practical route into clinician-reviewed care; the medical evaluation still determines whether any prescription is appropriate.
Who may not be a good candidate for PT-141?
PT-141 is not a fit for everyone. Cardiovascular history, blood pressure, medication list, mental health, hormones, pain, and relationship context can all change the risk-benefit picture.
Cardiovascular risk, blood pressure, and heart-rate considerations
The FDA label for Vyleesi reports transient increases in blood pressure and decreases in heart rate after dosing. It states Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease 1.
Low libido caused by medications, relationship factors, mental health, hormones, or other conditions
HSDD and low libido can have many causes. Consensus guidance for female sexual dysfunction emphasizes a biopsychosocial evaluation that considers medical conditions, mood, relationship factors, medications, pain, and hormonal status before choosing treatment 4.
Why eligibility requires a clinician’s review
A clinician review helps separate a desire disorder from other treatable issues, such as depression, genitourinary syndrome of menopause, medication side effects, thyroid disease, or relationship distress. That is why online checkout alone is not a safe substitute for care.
What side effects and safety issues should you know before buying PT-141?
Bremelanotide can cause side effects even when used as a prescription medicine. The most important safety issues are nausea, flushing, headache, injection-site reactions with the approved injectable product, and temporary blood pressure and heart-rate changes 1, 3.
Nausea, flushing, headache, and injection-site reactions reported with bremelanotide
In clinical trials and labeling, nausea was the most common adverse reaction with Vyleesi, and flushing, headache, vomiting, cough, fatigue, and injection-site reactions were also reported 1, 3. These effects matter because a medicine can be effective for some people and still not be tolerable for others.
Temporary blood pressure increase and heart-rate decrease
The Vyleesi label describes a transient blood pressure increase that generally peaked soon after dosing and usually resolved within 12 hours, along with a corresponding heart-rate decrease 1. People with cardiovascular disease or uncontrolled hypertension need careful screening.
Why side effects may differ between approved and compounded forms
The best-known safety data come from studied bremelanotide injections, not every compounded PT-141 formulation. Compounded formulations may use different routes, strengths, excipients, or packaging, so results and side effects are not established in the same way as an FDA-approved product 9.
Where is bremelanotide injected, and does that apply to all PT-141 products?
Vyleesi labeling describes subcutaneous bremelanotide injection in the abdomen or thigh before anticipated sexual activity, with label-specific limits and instructions 1. That does not mean patients should follow online injection instructions for research peptides, and it does not describe Chia’s listed PT-141 form.
What the approved injectable product labeling and clinical literature describe
The FDA-approved product is a subcutaneous injection, and clinical reviews describe the studied 1.75 mg dose given under the skin before sexual activity in women with HSDD 1, 2. That is a label and study description, not personal dosing advice.
Why patients should not use online instructions to self-inject research peptides
Research-use peptide pages may mention vials, reconstitution, or lab handling, but those materials are not intended for self-treatment. Injecting a product that is not dispensed for human use adds risks around sterility, identity, dosing accuracy, and adverse-event follow-up 7, 8.
Why Chia’s listed PT-141 form is nasal spray, not injection
Chia’s current catalog lists PT-141 nasal spray only. If you are evaluated through Chia, your provider-guided plan is based on that listed form and your medical history, not on injection instructions from forums or research-chemical websites.
What should you ask a clinician before using PT-141?
PT-141 should be discussed in the context of your whole sexual health, not as a stand-alone online purchase. Good questions focus on diagnosis, causes, risks, alternatives, and follow-up.
- 1What is most likely causing the libido concern in my case?
- 2Does my history fit HSDD, female sexual interest/arousal disorder, erectile dysfunction, medication-related low libido, or something else?
- 3Do I have blood pressure, heart, medication, pregnancy, or mental-health factors that change the risk?
- 4Are there safer or better-studied options for my situation, such as counseling, medication changes, hormone evaluation, vaginal pain treatment, or PDE5 inhibitors when erectile dysfunction is the main issue?
- 5How will we decide whether it is helping, and what side effects should make me stop and seek care?
Professional guidance on female sexual dysfunction stresses careful diagnosis and shared decision-making because sexual desire concerns often have more than one cause 4. That is also why a prescription is not guaranteed after an online visit.
3-min quiz
Start with a clinician-reviewed path
If you want to explore whether PT-141 nasal spray fits your goals, start Chia’s online visit. You can review PT-141 or the Spark protocol, then complete the quiz. A licensed provider reviews your information and prescribes only when clinically appropriate.
FAQ
Yes. PT-141 is another name for bremelanotide, a melanocortin receptor agonist that acts in central nervous system pathways involved in sexual desire and arousal.
Bremelanotide is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. Compounded PT-141 is not FDA-approved, and research-use PT-141 peptides are not intended for human use.
PT-141 has been studied in men, including for erectile dysfunction, but it is not FDA-approved for erectile dysfunction. Men considering it need clinician review because the evidence, risks, and alternatives differ from person to person.
You may see PT-141 sold online without a prescription as a research chemical, but those products are not intended for human use. For human treatment, safer access should involve a licensed clinician and a prescription when appropriate.
No. The FDA-approved bremelanotide product, Vyleesi, is a subcutaneous injection for a specific HSDD indication. Chia currently lists compounded PT-141 as nasal spray, which is not FDA-approved.
The approved Vyleesi label describes use before anticipated sexual activity, but timing and expectations depend on the prescribed product and the person. Do not use online timing or dosing instructions as medical advice.
People with uncontrolled high blood pressure or known cardiovascular disease may not be candidates for bremelanotide. PT-141 can cause temporary blood pressure increases and heart-rate changes, so clinician review is important.
PT-141 acts through melanocortin receptor signaling in the brain and is mainly discussed for desire and arousal. Viagra, or sildenafil, is a PDE5 inhibitor that mainly improves blood-flow signaling involved in erections.
References
- 1.U.S. Food and Drug Administration. Vyleesi (bremelanotide injection) Prescribing Information. 2019.
- 2.Dhillon S, Keam SJ. Bremelanotide: A Review in Hypoactive Sexual Desire Disorder in Premenopausal Women. Drugs. 2019.
- 3.Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019.
- 4.Parish SJ, Goldstein AT, Goldstein SW, et al. Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions—Part II. Journal of Sexual Medicine. 2016.
- 5.Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An Effect on the Subjective Sexual Response in Premenopausal Women by Bremelanotide. Journal of Sexual Medicine. 2006.
- 6.Diamond LE, Earle DC, Rosen RC, et al. Double-blind, Placebo-controlled Evaluation of the Safety, Pharmacokinetic Properties and Pharmacodynamic Effects of Intranasal PT-141, a Melanocortin Receptor Agonist, in Healthy Males and Patients with Mild-to-Moderate Erectile Dysfunction. International Journal of Impotence Research. 2004.
- 7.Nationwide Peptides. PT-141 – Bremelanotide Peptide product information. 2026.
- 8.American Peptides. PT-141 – Research Peptide product information. 2026.
- 9.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2024.
- 10.Clayton AH, Kingsberg SA, Goldstein I. Evaluation and Management of Hypoactive Sexual Desire Disorder. Sexual Medicine. 2018.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
